Last updated: 11/04/2018 08:08:40
Investigate two trial models; Vienna Challenge Chamber (in and out of season) and Park Study (in season) using a drug for seasonal allergic rhinitis
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A randomised, double blind, placebo controlled, two way crossover, three phase study to investigate the trial models; Vienna Challenge Chamber, in and out of season and Park study in season and the clinical efficacy of repeat doses of fluticasone propionate in subjects with seasonal allergic rhinitis (SAR).
Trial description: The aim of the study is to investigate the trial models, Vienna Challenge Chamber (VCC), in and out of season, and Park Study in season and the clinical efficacy of repeat doses of fluticasone propionate in subjects with seasonal allergic rhinitis.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Weighted mean major symptom complex (MSC) sneeze, nasal itch, rhinorrhoea and itching eyes following 5 hours spent in the Vienna Challenge Chamber (VCC), in and out of season, and 5 hours in the Park Study in season.
Timeframe: 0-5 hour after last dose in either model
Secondary outcomes:
Weighted mean global symptom score in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Symptoms of local irritancy in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Quality of life in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Weighted mean nasal airflow resistance in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Adverse Events in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Forced Expiratory Volume in 1 second (FEV1) in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Mean nasal secretion weight in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Weighted mean eye symptom score in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Weighted Mean Total Nasal Symptom Score (TNSS) in both in-Chamber and Park studies
Timeframe: 0-5 hour after last dose in either model
Time until a 20% reduction is seen in TNSS, mean and global symptom scores, Nasal airflow resistance, Nasal secretion weight and FEV1
Timeframe: 2 hour after last dose in either model
Interventions:
Other: Matched FPANS placebo
Drug: Fluticasone Propionate
Enrollment:
41
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Rhinitis, Allergic, Seasonal
Product
fluticasone propionate
Collaborators
Not applicable
Study date(s)
March 2006 to November 2006
Type
Interventional
Phase
1/2
Participation criteria
Sex
Female & Male
Age
18 - 50 Year
Accepts healthy volunteers
none
- The subject is healthy. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests.
- They have a history of seasonal allergic rhinitis
- Pregnant or nursing females.
- Female subjects of childbearing potential who are unwilling or unable to use an appropriate method of contraception [i.e. implants of levonorgestrel, injectable progesterone, an acceptable intra-uterine device (IUD) (any IUD with a failure rate of less than 1% per year), oral contraceptives or any other method with a failure rate of <1% per year] for at least two weeks prior to the first dose of study medication and should continue using the same contraceptive measure until the final pregnancy test has been performed (not less than 72 hours after treatment). Alternatively they may be surgically sterilised (refer to section 6.4) or remain abstinent for 2 weeks before exposure to study drug.
Inclusion and exclusion criteria
Inclusion criteria:
- The subject is healthy. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests.
- They have a history of seasonal allergic rhinitis
- Exhibit a moderate response to 1500 grass pollen grains per cubic metre after 2 hours in the Vienna Challenge Chamber at screening or within 12 months preceding the screening visit. A moderate response is defined as a total nasal symptom score of at least 6. (Total nasal symptom score is the sum of obstruction, rhinorrhoea, itch and sneeze, each of which has been scored on a scale from 0 to 3).
- They have a positive skin prick test (wheal size equal to or more than 4mm) for grass pollen at or within the 12 months preceding the screening visit.
- They have a positive RadioAllergoSorbent Test (RAST) (equal to or more than class 2) for grass pollen at or within the 12 months preceding the screening visit.
- They have demonstrated an ability to use the intranasal spray
- There are no conditions or factors which would make the subject unlikely to be able to stay in the chamber for 5 hours.
- They are capable of giving informed consent which includes compliance with the requirements and restrictions listed in the consent form
- They are available to complete all study measurements
Exclusion criteria:
- Pregnant or nursing females.
- Female subjects of childbearing potential who are unwilling or unable to use an appropriate method of contraception [i.e. implants of levonorgestrel, injectable progesterone, an acceptable intra-uterine device (IUD) (any IUD with a failure rate of less than 1% per year), oral contraceptives or any other method with a failure rate of <1% per year] for at least two weeks prior to the first dose of study medication and should continue using the same contraceptive measure until the final pregnancy test has been performed (not less than 72 hours after treatment). Alternatively they may be surgically sterilised (refer to section 6.4) or remain abstinent for 2 weeks before exposure to study drug.
- On examination the subject is found to have any structural nasal abnormalities or nasal polyposis, a history of frequent nosebleeds, recent nasal surgery or recent (within 3 weeks) or ongoing upper respiratory tract infection which in the responsible physician's opinion renders the subject unsuitable for participation in the study
- The subject has any respiratory disease other than mild stable asthma that is controlled with occasional use of as-needed short-acting beta-agonists and associated with normal lung function.
- The subject is likely to be unable to abstain from salbutamol use for 8 hours before a challenge
- The subject has a history of drug or other allergy that, in the opinion of the responsible physician, contraindicates their participation.
- The subject has participated in a study with a new molecular entity during the previous 3 months or in any clinical study in the previous 2 months
- The subject is concurrently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
- The subject is currently taking regular (or a course of) medication whether prescribed or not, including steroids, vitamins and herbal remedies (e.g. St. John's Wort). Paracetamol and occasional as needed use of short-acting beta agonists is permitted
- The subject regularly, or on average, drinks more than 3 units of alcohol per day
- where 1 unit = ½ pint of beer (284milliliteres mL), or 1 glass of wine (125mL), or 1 measure of spirit (25mL).
- The subject is at risk of non-compliance with the study procedures/restrictions.
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2006-20-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website